HeidiCraytonMD

Neurology • Vienna, VA

Neuroimmunology/Multiple Sclerosis

Medical Director at MS Center of Greater Washington

Join to view full profile

Dr. Crayton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Crayton's full profile

Already have an account?

Office
8320 Old Courthouse Rd
Suite 400
Vienna, VA 22182
Phone+1 703-226-4000

Fax+1 703-226-4010
Is this information wrong?

Education & Training

MedStar Health/Georgetown University HospitalResidency, Neurology, 1994 - 1997
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1993 - 1994
MCP-Hahnemann College of MedicineClass of 1993

Certifications & Licensure

VA State Medical License 1997 - 2024
DC State Medical License 1997 - 2013
MD State Medical License 1997 - 1998
PA State Medical License 1993 - 1994
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
Completed
Phase 2
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
Terminated
Phase 3

Publications & Presentations

PubMed

25 citations
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Rafael Arroyo González, Mariko Kita, Heidi Crayton, Eva Havrdova, David Margolin, Stephen Lake, Gavin Giovannoni, II Investigators> ;Multiple Sclerosis. 2017 Sep 1
7 citations
Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program.
Heidi Crayton, Matthew F Sidovar, Stanley Wulf, Amy Guo> ;The Patient. 2015 Jun 1
29 citations
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: ...
Jonathan Calkwood, Bruce A.C. Cree, Daniel Kantor, Brian Steingo, Luigi Barbato, Ron Hashmonay, Neetu Agashivala, Kevin McCague, Nadia Tenenbaum, Keith R. Edwards, Hei...> ;BMC Neurology. 2014 Nov 26
65 citations
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study...
Edward Fox, Keith R. Edwards, Gordon Burch, Daniel Wynn, Chris LaGanke, Heidi Crayton, Samuel F. Hunter, Cynthia Huffman, Edward Kim, Linda Pestreich, Kevin McCague, L...> ;Multiple Sclerosis and Related Disorders. 2014 Sep 1
90 citations
Managing the symptoms of multiple sclerosis: a multimodal approach.
Heidi Crayton, Howard Rossman> ;Clinical Therapeutics. 2006 Apr 1
81 citations
A multimodal approach to managing the symptoms of multiple sclerosis.
Heidi Crayton, Rock Heyman, Howard Rossman> ;Neurology. 2004 Dec 14
625 citations
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.
Niveditha Mohan, Evelyne T. Edwards, Thomas R. Cupps, Patrick J. Oliverio, Glenn D. Sandberg, Heidi Crayton, John R. Richert, Jeffrey Siegel> ;Arthritis and Rheumatism. 2001 Dec 1
Join now to see all

Press Mentions

I Have MS and I’m Very LuckyMay 22nd, 2018

External Links

MS Center of Greater Washingtonhttp://www.drcrayton.com